New thread probably better idea
Edison report
http://www.investing.com/analysis/alchemia:-pivotal-phase-iii-result-due-in-q214-203867
a snip
"Valuation: Potentially a multiple of the current price
Alchemia believes HA-Irinotecan could generate between US$465m and US$1.5bn in annual sales (depending on the degree of PFS improvement). With mid-teen royalties, sizeable milestones and potential launch dates of H215 in the US and H116 in Europe, the upside of a successful trial outcome is significant. However, an equivocal or negative result would similarly lower the valuation materially."
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable